The NHS will have to divert £45bn from essential services to pay for new medicines under the terms of the UK-US trade deal agreed last December, leading to more than 200,000 avoidable deaths of patients, analysis has found.
Ministers have defended the deal as a way of helping British drug exports to the US avoid tariffs, and giving patients in England access to potentially life-extending drugs that would otherwise be denied.
